International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
Authors
Keywords
-
Journal
BLOOD
Volume 117, Issue 23, Pages 6063-6073
Publisher
American Society of Hematology
Online
2011-03-30
DOI
10.1182/blood-2011-02-297325
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multiple Myeloma, Venous Thromboembolism, and Treatment-Related Risk of Thrombosis
- (2011) Elena Zamagni et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency
- (2010) Patrizia Tosi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma
- (2010) C. B. Reeder et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
- (2010) S. Bringhen et al. BLOOD
- Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma
- (2010) Jonathan L. Kaufman et al. CANCER
- Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD)
- (2010) M. Wang et al. Hematology
- Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
- (2010) Asher A. Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
- (2010) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
- (2010) Bart Barlogie et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
- (2010) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
- (2010) Marco Ladetto et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
- (2010) María-Victoria Mateos et al. LANCET ONCOLOGY
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
- (2010) Michel Delforge et al. LANCET ONCOLOGY
- Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
- (2010) S K Kumar et al. LEUKEMIA
- Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
- (2010) H Avet-Loiseau et al. LEUKEMIA
- Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
- (2009) D. Reece et al. BLOOD
- How I treat multiple myeloma in younger patients
- (2009) A. K. Stewart et al. BLOOD
- The role of complete response in multiple myeloma
- (2009) J.-L. Harousseau et al. BLOOD
- Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
- (2009) P. Kapoor et al. BLOOD
- Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
- (2009) S. Kumar et al. BLOOD
- A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
- (2009) H. M. Lokhorst et al. BLOOD
- Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma
- (2009) Sagar Lonial et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma
- (2009) William I. Bensinger et al. BRITISH JOURNAL OF HAEMATOLOGY
- Thalidomide Maintenance in Multiple Myeloma: Certainties and Controversies
- (2009) Michele Cavo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma
- (2009) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma
- (2009) Michele Cavo et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
- (2009) Andrew Spencer et al. JOURNAL OF CLINICAL ONCOLOGY
- Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
- (2009) Jayesh Mehta JNCI-Journal of the National Cancer Institute
- Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
- (2009) Sergio Giralt et al. JNCI-Journal of the National Cancer Institute
- Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
- (2009) A. Kumar et al. JNCI-Journal of the National Cancer Institute
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
- (2009) R Fonseca et al. LEUKEMIA
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
- (2009) C B Reeder et al. LEUKEMIA
- Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
- (2008) Shaji K. Kumar et al. AMERICAN JOURNAL OF HEMATOLOGY
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
- (2008) H. Ludwig et al. BLOOD
- Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
- (2008) A. Palumbo et al. BLOOD
- Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
- (2008) A. A. Argyriou et al. BLOOD
- Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up
- (2008) Rakesh Popat et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
- (2008) Mauricio Pineda-Roman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy
- (2008) Eric Vickrey et al. CANCER
- Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
- (2008) Bart Barlogie et al. CANCER
- Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
- (2008) Asher Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
- (2008) J F San-Miguel et al. LEUKEMIA
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
- (2007) William Bensinger JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started